TPTH will it replace NPTH in portfolio? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : TPTH will it replace NPTH in portfolio?

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Joseph Ziebarth who started this subject	10/8/2001 5:45:52 PM
From: Joseph Ziebarth	Read Replies (1) of 8

This may well be the start of good times. TriPath jumps on FDA ok thin-layer prep (TPTH) By Michael Baron TriPath Imaging (TPTH) is up $1.40, or 27.7 percent, to $6.45, after the Burlington, N.C., cancer screening and diagnostics products said it has received approval from the Food and Drug Administration to include the screening of its AutoCyte PREP thin-layer preparations on the AutoPap primary screening system. "We are very pleased to have received FDA approval to screen AutoCyte PREP slides with the AutoPap(R) System," said Paul Sohmer, the company's president, chairman, and CEO, in a press release. "We believe that the clinical performance and economic efficiencies gained with our integrated solution offer the flexibility that our customers require as they transition from conventional testing to thin-layer Pap smear testing."

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next